Novartis has agreed to acquire UK-based biotechnology company Myricx Bio in a transaction valued at up to $1.5 billion.
The Swiss pharmaceutical group announced the deal on Monday, signaling a continued push to bolster its research and development portfolio through strategic acquisitions.
The deal adds to a busy period for M&A in the life sciences sector, following recent high-profile transactions such as Merck KGaA’s $11.
The agreement is expected to close in the second half of 2026, subject to customary regulatory approvals and other closing conditions.
Novartis stated that the acquisition would integrate Myricx Bio’s capabilities into its existing operations, though specific details regarding the target’s therapeutic focus were not immediately disclosed in the initial announcement.
The move comes as major pharmaceutical companies continue to seek external innovation to offset patent expirations and sustain growth.
The deal adds to a busy period for M&A in the life sciences sector, following recent high-profile transactions such as Merck KGaA’s $11.3 billion acquisition of US-based Bio-Techne.